Minnetronix Medical Awarded National Institutes of Health Grant for Proprietary Neurapheresis Product that Removes Blood from Spinal Fluid
October 20, 2020 - Minnetronix Medical, Inc.
Fast Track Small Business Innovation Research Funding Accelerates Minnetronix’s Platform Strategy to Bring Adaptable Technology and Market-Ready Products to Customers
The presence of blood in the spinal fluid increases the risk of complications such as cerebral vasospasm, edema, hydrocephalus, or stroke. The Neurapheresis System enables expedited removal of blood and blood byproducts from the cerebrospinal fluid. This has been shown to shorten hospital stays, reduce use of hospital resources and improve outcomes for patients, thereby reducing the healthcare economic burden.1-3
“Rapid removal of the toxins that are released into the cerebrospinal fluid when an aneurysm ruptures could be game changing and improve outcomes for patients who suffer a subarachnoid hemorrhage,” said Christopher Kellner, MD, director of the Intracerebral Hemorrhage Program at Mount Sinai and site investigator of the clinical trial at Mount Sinai. “Winning support from the NIH is another important step to completing the research necessary to evaluate the impact of this treatment strategy.”
“What fantastic validation from the medical community and the NIH that we are able to identify unmet needs and develop meaningful solutions,” said Aaron McCabe, PhD, director of research and development at Minnetronix, who is leading the Neurapheresis project. “The Minnetronix team relied on 25 years of experience to develop the platform — from concept to commercialization. Whole product solutions like this represent an expansion of our traditional offerings and create new ways for us to partner with our customers.”
The grant is the second milestone Minnetronix has announced in a month. Recently, it received FDA clearance for the MindsEye™ Port, an expandable deep brain access system used in neurosurgical procedures, that represents the launch of the company’s first technology platform. Neurapheresis is part of the company’s second platform launch.
About Minnetronix Medical
Since 1996, Minnetronix Medical has accelerated medical device breakthroughs as a design, development and manufacturing partner to leading device companies around the world. Today, through a commitment to life-cycle efficiency, opportunity realization, and increased utility, the organization is driving innovation in key technology segments, including RF/EM energy, fluid and gas management, optical systems, and stimulation and active wearables. From design to commercialization to whole product solutions, Minnetronix brings expansive industry insight and intentional technical acumen, delivering better medical devices to market, faster. Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing email@example.com.